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Abstract
Background: Facilitating appropriate and safe prescribing of opioid medications for chronic pain management in
primary care is a pressing public health concern. Interdisciplinary team-based models of primary care are exploring
the expansion of clinical pharmacist roles to support disease management for chronic conditions, e.g. pain. Our
study aims to 1) identify roles clinical pharmacists can assume in primary care team based chronic pain care
processes and 2) understand the barriers to assuming these expanded roles.
Methods: Setting: Veterans Health Administration (VA) has implemented an interdisciplinary team-based model for
primary care which includes clinical pharmacists. Design: We employed an inductive two part qualitative approach
including focus groups and semi-structured interviews with key informants. Participants: 60 members of VA primary
care teams in two states participated in nine preliminary interdisciplinary focus groups where a semi-structured
interview guide elucidated provider experiences with screening for and managing chronic pain. To follow up on
emergent themes relating to clinical pharmacist roles, an additional 14 primary care providers and clinical pharmacists
were interviewed individually. We evaluated focus group and interview transcripts using the method of constant
comparison and produced mutually agreed upon themes.
Results: Clinical pharmacists were identified by primary care providers as playing a central role with the ongoing
management of opioid therapy including review of the state prescription drug monitoring program, managing laboratory
screening, providing medication education, promoting naloxone use, and opioid tapering. Specific barriers to clinical
pharmacists role expansion around pain care include: limitations of scopes of practice, insufficient institutional support
(low staffing, dedicated time, insufficient training, lack of interdisciplinary leadership support), and challenges and
opportunities for disseminating clinical pharmacists’ expanded roles.
Conclusions: Expanding the role of the clinical pharmacist to collaborate with providers around primary care based
chronic pain management is a promising strategy for improving pain management on an interdisciplinary primary care
team. However, expanded roles have to be balanced with competing responsibilities relating to other conditions.
Interdisciplinary leadership is needed to facilitate training, resources, adequate staffing, as well as to prepare both clinical
pharmacists and the providers they support, about expanded clinical pharmacists’ scopes of practice and capabilities.
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Background
Pain is a complex condition impacted by various bio-
logical, psychological, and social factors and is usually a
high treatment priority for patients seeking care [1, 2].
Due to its complexity, chronic pain can be incredibly
difficult to manage. Improving processes of care for
chronic pain is a public health priority [3]. This is due to
both the high prevalence of chronic pain diagnoses as
well as the risks associated with inadequate management
[4]. Since a majority of chronic pain is managed in pri-
mary care settings, primary care teams are increasingly
overburdened by and not fully equipped to manage all
of the complex, competing demands of patients with
pain [5, 6]. With expanded patient panel sizes (the num-
ber of patients assigned to a specific provider) and lim-
ited appointment times, clinicians face prioritizing
individual demands of specific medical conditions over
other patient concerns.
These complex challenges can be particularly prob-
lematic in the Veteran’s Health Administration (VA)
where providers are working with populations that ex-
perience high rates of chronic disease, including pain
and other comorbid conditions [7]. The VA is the largest
integrated health care system in the United Sates.
VA cares for over nine million Veterans and is com-
prised of 170 medical centers and 1063 outpatient
clinics [8]. In 2010, the VA implemented an interdiscip-
linary team-based model of primary care called
patient-aligned care teams (PACTs). These teams include
primary care providers (PCPs), nurses, and administrative
staff, and are supported by other clinicians including li-
censed clinical pharmacists [9–12]. Expanding roles of cli-
nicians such as advanced practice nurses and clinical
pharmacists, to include top of license tasks such as pre-
scribing, is conceptualized as central to improving chronic
disease management while minimizing the burden on in-
dividual PCPs.
One strategy being explored to support chronic dis-
ease management involves embedding clinical pharma-
cists in primary care to facilitate patient education,
supplemental patient interaction, and population man-
agement activities [11, 13–16]. Population management
comprises reviewing the entire population of patients
and proactively identifying risks; risk of inappropriate
opioid use for pain management is an important public
health concern. Some of the expanded clinical responsi-
bilities a clinical pharmacist can assume around pain
care include: ongoing reassessment, monitoring, and
management of opioid therapy in conjunction with
medication renewal, review of state prescription drug
monitoring programs, and medication education. Some
clinical pharmacists are specializing in pain management
to support teams with complex pain patients, opioid risk
management, opioid education, opioid titration, opioid
screening, and naloxone distribution [15]. When clinical
pharmacists are involved in an interdisciplinary team,
clinics have reported a decrease of burden on PCPs and
improved patient satisfaction [17].
To inform future implementation efforts we queried
all providers involved in primary care based pain man-
agement to better understand clinical pharmacists’
current and potential roles with pain management. Fur-
ther, the clinical pharmacists we interviewed included
several layers of pharmacy leadership, which helped us
explore system level barriers to assuming expanded
roles. Existing literature suggests that expanding phar-
macist’s clinical roles for chronic pain care may
minimize adverse effects patients experience and thus
improve patient care [18]. Our study aims to 1) identify
roles clinical pharmacists can assume in primary care
team based chronic pain care processes and 2) under-
stand the barriers to assuming these expanded roles.
Methods
Overview
The data for this qualitative analysis was collected as
part of the Effective Screening for Pain (ESP) study, a
mixed methods analysis of pain screening, assessment,
and management methods [19]. All study procedures
were approved by the VA central Institutional Review
Board (IRB Project ID 13–08). Under ESP we had mul-
tiple waves of primary data collection. Verbal consent to
participate and record all focus groups and interviews
was obtained at the beginning of each session.
Setting
This study was conducted in the context of the VA. The
VA relied on the patient centered medical home model
(PCMH) to provide out-patient primary care. The VA’s
version of PCMH is called patient aligned care teams
(PACT). Under PACT, interdisciplinary providers work
together to provide continuous, coordinated, high qual-
ity care. PACT patients are assigned to a specific inter-
disciplinary care team (including a primary care
provider, registered nurse, licensed practical nurse, and
clerk). These small interdisciplinary teams are supported
by other providers such as behavioral and mental health
providers, social workers, and licensed clinical pharma-
cists. Clinical pharmacists are those who participate in
prescribing, patient education, population management
activities, and possibly academic detailing or education
to other providers on evidence based prescribing
practices.
Wave one data
In wave one, we conducted nine focus groups including
a total of 60 providers working on interdisciplinary pri-
mary care teams in two large VA Medical Centers in
Giannitrapani et al. BMC Family Practice  (2018) 19:107 Page 2 of 9
California and Oregon, as well as associated community
based outpatient clinics [20–22]. Interdisciplinary team
members invited to participate in the focus groups in-
cluded PCPs, registered nurses, licensed practical nurses,
clerks, psychologists, social workers and clinical pharma-
cists. Focus groups occurred between 2013 and 2014
and lasted approximately one hour.
Focus group analysis
Trained facilitators used a semi-structured interview guide
to elucidate provider experiences with screening, assess-
ment, and management of chronic pain. All focus groups
were audio recorded, professionally transcribed, and tran-
scripts were cleaned to remove identifying information. All
analyses were conducted using qualitative analytic software
ATLAS.ti. [23]. An initial code list was developed and iter-
ated via the dual coding of two transcripts. The final code
list was then systematically applied to every transcript. After
primary coding, secondary coders reviewed each transcript
for inconsistencies. Team meetings fostered consensus for
code development and facilitated resolutions for coding dis-
crepancies. ESP investigators evaluated transcribed inter-
views using the method of constant comparison [24] and
produced mutually agreed upon themes. The method of
constant comparison continued until we reached theoretical
saturation on each theme. Presentation of results to PACT
team primary care providers served as a member check and
confirmed content validity. Expansion of clinical pharmacist
roles emerged as a supportive factor to PACT pain manage-
ment. As a result of this early finding we conducted further
investigation through a second wave of interviews.
Wave two data
The second wave of interviews consisted of individual
semi-structured interviews with 14 key participants. The
participants included: PCPs (general internists and nurse
practitioners) as well as multiple types of clinical phar-
macists (primary care, mental health, pain management,
and pharmacy leadership). These semi-structured inter-
views occurred at Portland and Palo Alto in 2016. The
interview guild included specific probes about how clin-
ical pharmacists are involved in chronic pain manage-
ment (see Table 1). Key stakeholders were identified
using a snowball sampling approach [25], and we relied
heavily on referrals for recruitment. Snowball sampling
represented the best method we had to access the clin-
ical pharmacists, as we did not have a master list of
people in this role. Through introductions we were able
to recruit a meaningful number that we may not have
have been able to access via cold calling or emails.
Wave two analysis
Informed by grounded theory [24], investigators [KG
and DV] then used an open coding approach on the
wave two interview transcripts to identify emergent
themes. This method was selected to help us divide the
textual data into conceptual components. Specifically,
through iteration and consensus the entire investigator
team reviewed all quotes associated with barriers and
characterized emergent themes around barriers to the
clinical pharmacists’ role expansion. This process con-
tinued until theoretical saturation was reached on each
barrier. After the interviews were completed, one clinical
pharmacist interviewee [JM] joined the investigator team
during the analytic phase to provide expert guidance on
contextualizing the results.
Results
Respondents included 60 focus group participants in
nine focus groups and 14 semi-structured interview re-
spondents. Below we present first the results of the focus
groups which explain the roles a clinical pharmacist can -
assume, second, we present results from the induvial in-
terviews which cluster into three themes.
Focus group results
The focus groups with different providers revealed sub-
stantial support across professions for an enhanced role
of clinical pharmacists. PACT providers advocated for
pharmasists to assume responsibility in the team
process.
Table 1 Focus Group and Interview Guide Questions
Wave One Focus group questions
Who in your opinion is the most appropriate person to screen for pain
and why?
Who in your opinion is the most appropriate person to assess pain and
why?
Other than the finding that the patient has pain, what information
about a patient’s pain is most useful to you in:
a) preparing to assess pain
b) actually assessing pain
c) guiding your treatment/management plan for pain
What are the roles of different staff members [PCP, RN, LVN, Clerk,
Mental health, Pharmacist etc...] in getting pain information? Assessing
pain? Managing pain?
Wave Two Semi-structured interview probes relating to pharmacist
role expansion
How are pharmacists involved in primary care chronic pain
management currently?
How could their role expand?
What are the barriers to role expansion?
Would they need additional training or licenses?
How does the pharmacist interact with the rest of the team about pain?
For what types of conditions and concerns are they involved?
What is the role of the academic detailer relating to pain medications?
Do you have any thoughts about how we could improve pharmacist
directed pain management of ‘at risk’ Veterans?
What do you think about pharmacists taking on responsibility for
monitoring and providing medications to such Veterans?
Do you anticipate any challenges for pharmacists taking on that role?
Are there others on the team who would be better equipped to take it
on? Who (Nurses, Social workers, etc.)?
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“Overall if by the time I saw a patient they had been
pre-screened or processed and behind the scenes some-
body in pharmacy… had run the CURES reports
[CURES: California’s Controlled Substance Utilization
Review and Evaluation System] and arranged for the
interval of tox screens [urine toxicology screening] …
[and] were aware of any escalations in terms of early
refill-if that information was available... [Then] I didn’t
have to worry about it, that’d be helpful.” [PCP]
Additionally, PCPs felt having the clinical pharmacists
involved in refill management for patients on long term
opioid therapy may offer a team strategy to minimize
the risk of drug abuse.
“If the pharmacy believes that they're not due for
them, they will not give it [opioid pain medication]
to them. Because you have some patients that they
just got the pain medication today, come back the
following day.... Because it was lost or they robbed
their house. Of all the valuables, it's only the
Vicodin that was stolen? It's very common… Our
pharmacy department, they are very smart, too. So
they tell them [patient], “Okay. Then come back
every week.” And if they lose it again, “Then come
back every day.” Instead of giving them the whole
supply.” [PCP]
PCPs also described including clinical pharmacists
on the team as particularly useful for reconciling pre-
scriptions from providers in multiple departments. In
cases where acute pain, dental pain for example, com-
bines with chronic pain, clinical pharmacist involve-
ment can prevent patients exhibiting drug seeking
behavior from accessing inappropriate quantities of
opioid medications.
“We've recently had a patient— complaining he was in
pain. But the first thing he said was, “I'm not a drug
addict, I have a family of four, I'm gainfully employed, I
go to school,” … he was placed on Tramadol… He took
the Tramadol [home]… He came back a week later; he
[should] still have more Tramadol, [but] claimed he
hadn't used it. He said he had a [new] dental problem,
went up to Dental, requested something stronger. He
had an extraction; he was ordered Tylenol #3. He took
that, but he had gotten the Vicodin the three days
before… he came back … Requesting more Vicodin. He
also went to the pharmacist, and the pharmacist said,
“You can't get it. It's not due.” [PCP]
PCPs also highlighted the valuable contribution clin-
ical pharmacist run clinics make in coordinating care
with pain and substance abuse specialists.
“For the chronic pain patients… they [clinical
pharmacists] have the chronic or renewal clinics for
pain medications and they actually do the assessments
there… those clinics are pharmacist run, but they work
very closely with both the actual pain clinic and the
substance abuse clinics.” [PCP]
“So if the substance abuser has issues, they can
actually go easily right into the pain clinic and if a
pain clinic patient has a problem they go right easily
into the substance treatment program and then the
[clinical pharmacist run] renewal clinic does a lot of
monitoring-they monitor the tox screens, they monitor
the CURES reports, they monitor the pain levels if
something needs to be adjusted.” [PCP]
Interview results
Three core themes were identified: limitations of
scopes of practice, insufficient institutional support,
and challenges and opportunities for disseminating
clinical pharmacists’ expanded roles. The quotes we
present below come from the clinical pharmacist in-
terviews and these themes were also present in the
PCP interviews.
Theme 1: Limitations of scopes of practice
1.1 Including pain management in a scope of practice
Some clinical pharmacists do not have a local scope of
practice for pain management.
“Currently my scope is only for the disease states I
mentioned earlier [diabetes, dyslipidemia, hypertension
or poly-pharmacy] and I don’t have a scope for pain.”
[Clinical Pharmacist]
“We’ve tried to get some of the PACT pharmacists to
help [with checking CURES report]; but, like I said,
that pushback -not written within our scope- has been
there.” [Pharmacy Leadership]
Variation in scopes of practice relating to prescribing
Some clinical pharmacists were not scoped to prescribe
controlled substances.
“We [clinical pharmacists] can’t order the [controlled]
medications. It just seems like something that would
be kind of [helpful] in terms of time-wise and provider-
wise” [Clinical Pharmacist]
In some states clinical pharmacists can prescribe con-
trolled substances, but providers may be unaware of
clinical pharmacists’ scopes of practices.
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I met with a new provider the other day for addiction
treatment services and was explaining my role as a
pharmacist, and a lot of them just aren’t even sure
that we have scopes of practice, that we actually see
patients and prescribe. [Clinical Pharmacist]
Theme 2: Insufficient institutional support
Low staffing
Staffing levels pose a challenge for clinical pharmacists
who wish to spend time doing additional training for
having pain in their scope of practice.
“Another problem is… the staffing… in order to take on
additional training, then I would have to be taken away
from my responsibilities in order to get the hours in to
get the scope [to work on pain].” [Clinical Pharmacist]
Insufficient local staffing may limit the time a clinical
pharmacist has to address both chronic disease and opi-
oid management.
“I don't think we have the manpower to…deal with the
chronic diseases—diabetes, hypertension, and lipids—and
also troubleshoot the [opioid] medication. So don't have
much time to deal with this pain thing.” [Clinical
Pharmacist]
Dedicated time
Clinical pharmacists consistently reported that lack of
time was a barrier to taking on additional tasks such as
managing pain medication and reporting.
“For CURES [reporting] I don’t think that would be the
lack of training [to take on that work]. I think that’s
just maybe the time. They say that there’s a time
limitation.” [Clinical Pharmacist]
Clinical pharmacists identified that given their limited
time, they would benefit from guidance around where
their support would be best directed.
“We know that when it comes to coag [anticoagulation]
management and lipid management that they’re [PACT
clinical pharmacists] not needed as much as they were,
so there is time freeing up…what other disease states
does the health care system want them to help with,
whether it’s heart failure, COPD, pain. Where does
pain…fall in that?” [Clinical Pharmacist]
Some clinical pharmacists report that managing an as-
sortment of medical conditions can make it difficult to
become more involved with pain care.
“Right now we are responsible for… the anticoag
portion… It’s not something that I could just defer [to
work on pain]… now we decentralized anticoagulation,
so I’ll just follow all the Warfarin patients who belong to
my providers… it’s a little bit difficult because… I try to
schedule it as best as I can, but you just can’t really
control when patients come in or when new patients go
to the ER with a new blood clot. We do have set clinic
hours for pharm care, like, when we do see diabetics
but, other than that, I just have to fill in all my
anticoags whenever I can.” [Clinical Pharmacist]
Insufficient training
Some clinical pharmacists reported that they did not
think their experiences and skills were adequate to work
with pain management.
“There's not much courses or a lecture on pain
management…also, I don't have that much experience
[with pain] in terms of clinic to kind of learn from my
experience.” [Clinical Pharmacist]
Clinical Pharmacists also reported limited training op-
portunities in pain management.
“I [clinical pharmacist with pain specialty training]
would assume it’s [pain management] beyond what their
[PACT clinical pharmacists] current training is and that
they would need education.” [Clinical Pharmacist]
Lack of interdisciplinary leadership support
Support from leadership can facilitate implementing inter-
disciplinary team-based approaches to pain management.
“It’s been several things… Great leadership. So our
associate chief of primary care, as well as our nursing
leadership and myself [clinical pharmacist] and primary
care behavioral health, there’s four of us that get together.
We put education together and we go on the road and we
meet with everybody on a regular basis, and we just start
piecing things together and we would identify who on the
teams could help.” [Clinical Pharmacist]
Theme 3: Challenges and opportunities for disseminating
clinical pharmacists’ expanded roles
Perceived capabilities
Clinical pharmacists believe some PCPs may have lim-
ited awareness of their capabilities.
“I had stated at a meeting that we were piloting this
program and then I had sent out an email, but it still
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seemed like the providers weren’t familiar with what
we [clinical pharmacists] could do and what our
involvement could be, so I guess that dissemination of
education to the providers about what we could do
[would be helpful].” [Clinical Pharmacist]
Clinical pharmacists believe some PCPs do not know
what clinical pharmacists can take on and have precon-
ceived ideas as to what their roles are and can be.
“I met with a new provider the other day for addiction
treatment services and was explaining my role as a
pharmacist, and a lot of them just aren’t even sure that
we have scopes of practice, that we actually see patients
and prescribe. I think a lot of providers might still be
stuck in the idea that we’re still behind the counter in
the pharmacy, actually dispensing the medications. So
yeah, maybe more clarity on the different types of
pharmacists and their actual roles and how we can
collaborate together.” [Clinical Pharmacist]
Self-advocate
Clinical pharmacists may have to self-advocate and re-
mind PCPs of their capabilities.
“ I’ve met with the majority of them [PCPs] in either
staff meetings or one-on-one, and I’ve provided them
with my contact information so whether it’s Instant Mes-
saging, GUI, Outlook or calling me. Some of them attach
me on a note, but I pretty much always try to say, “If
you have any issues,” and even because I’m not a pain
specialist, that’s not my area of expertise, but I try to re-
solve whatever barrier and seeing how can I assist?
That’s just me kind of putting my face out there and try-
ing to let them know that this resource is available.”
[Clinical Pharmacist]
Promoting awareness of the referral process
Clinical pharmacists highlight the need to make PCPs
aware of the referral process to involve clinical pharma-
cists for pain medication management.
“Making sure that they’re [PCPs] aware of the referral
process to either have the pharmacist completes an e-
consult or a chart review with recommendations or
they can even refer patients to physically see the pain
pharmacist in clinic.” [Clinical Pharmacist]
Discussion
The implementation of expanded roles for clinical phar-
macists offers a central strategy to addressing the
expanding need for primary care provision in the con-
text of an impending physician workforce shortage. On
the other hand, role expansions are complex undertak-
ings. They require dedicated resources, training, and
leadership support to successfully transition the roles of
clinical pharmacists and surrounding PCPs with whom
they share care for complex patients. The PCMH model
highlights the ideal of “sharing the care” [26]. Explicitly
“sharing the care” for chronic pain patients with embed-
ded clinical pharmacists may ultimately improve patient
satisfaction with care and outcomes while reducing PCP
burnout associated with being alone in dealing with
complex patient concerns.
In this qualitative study we set out to characterize
interdisciplinary provider perspectives of how clinical
pharmacists have several opportunities to fulfill en-
hanced roles in relation to chronic pain management in
interdisciplinary primary care teams. We enumerate
multiple barriers clinical pharmacists face. The strategies
that may address emergent barriers included expanding
primary care clinical pharmacist training so that they
had a better understanding of pain as well as ensuring
the team had access to a clinical pharmacist with pain
expertise. Both PCPs and clinical pharmacists alike indi-
cated the importance of having a pain trained clinical
pharmacist, other providers could consult.
Given how quickly clinical pharmacy practice is evolv-
ing, it is not surprising that clinical pharmacists experi-
ence a number of barriers to expanding roles around
chronic pain care. To understand pharmacist role expan-
sion it is important to consider the historical distinctions
between medicine and pharmacy practices. Our results
indicate it is crucial to prepare for educating physicians
about potential top of license tasks for clinical pharma-
cists as these may challenge current pre-conceived
understandings of clinical pharmacist capabilities [27].
The barriers we identify in this study, namely low external
awareness of clinical pharmacist capabilities, capacity, and
prescribing authority, echo findings in other current stud-
ies [28, 29]. To overcome low awareness, interdisciplinary
dialogue about clinical pharmacist roles is essential.
A central tenant of implementation science is the belief
that if we understand and characterize individual barriers,
we can develop targeted implementation strategies to ad-
dress them [30]. In addition to training, resources, and
staffing which indicate health system level strategies, the
issue of how best to prioritize PCP and clinical pharmacist
time for addressing chronic pain requires further consid-
eration. Additionally, decentralization of care for some
conditions (e.g. all clinical pharmacists cover a few
anticoagulation patients each) versus use of clinical
pharmacist dedicated clinic time for a specific condition
(e.g. pain) can cause tension around clinical pharmacists’
workload distribution.
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What we learned from the provider focus groups is
pain is a condition where having multiple diverse
providers involved can add value, particularly in regard
to patient safety and monitoring activities. Known miti-
gation strategies of opioid overuse include regular moni-
toring and reassessment to provide opportunities to
minimize risks. Periodic reassessment allows the oppor-
tunity for tapering or discontinuing opioids [3]. Our
providers indicated that clinical pharmacists can clearly
play a key role in this monitoring process. In addition to
having technical expertise, clinical pharmacists added
value to the team by giving PCPs a way to say no about
prescribing high doses to patients. Simply having some-
one available representing the hospital policies or guid-
ance on safe prescribing, was supportive to primary care
providers trying to navigate difficult conversations with
drug seeking patients.
Additional strategies that have been called for to re-
duce inappropriate opioid prescribing include updated
protocols and clinical guidelines [31]. In many states
clinical pharmacists can prescribe controlled substances
and could take on the role of prescribing per protocol.
Clinical pharmacist led, academic detailing campaigns
have been demonstrated to reduce high-dose opioid pre-
scribing [32]. Clinical pharmacists scoped to deal with
pain may also have the ability to support patients
through tapering and medication changes.
At present, few medical schools offer sufficient train-
ing on addiction and pain management [33]. Conse-
quently, the average PCP may be underequipped to deal
with substance seeking patients with pain in primary
care. This is of concern as much of the prescribing for
chronic pain is occurring in primary care [5]. Having
clinical pharmacists on the interdisciplinary team to help
navigate complex situations and minimize risk of addic-
tion in chronic pain patients, could represent part of a
solution.
Our findings should be considered in the context of
the following limitations. First our study was conducted
within the VA health care system alone. The VA, how-
ever, while not generalizable to other settings does have
a population with a high prevalence of pain and an ex-
tensive history of addressing chronic pain in the primary
care setting [34]. This makes the VA a strong setting in
which to investigate pain practice processes. Secondly,
this study represents the sub analysis of a greater study
meaning that all of the methods are not specifically tai-
lored for this inquiry. For example, the initial focus
group data was collected for broader purposes. We do,
however, think that the benefits of hypothesis generation
(i.e. exploring the role of clinical pharmacists) outweigh
the limitations of being unable to identify what specific
team members were included. Third, although we con-
ducted a limited number of focus groups, sites varied by
location (rural, suburban, and urban), academic status,
and size, allowing us to describe the perspectives of pro-
viders based in multiple environments. Another major
limitation is that fundamentally, we do not know the
exact roles of participants in the focus groups. We
sought participation from all members of interdisciplin-
ary pact teams, including clinical pharmacists, but do
not know if clinical pharmacists were among those who
participated. This approach was supported by the IRB.
We were able to encourage broad participation of the
PACT team members, allowing them to be honest and
critical, because we did not collect any information on
who they were.
Due to this ambiguity in the focus groups, one of
the main reasons we conducted wave two of inter-
views was to explicitly capture the perspectives of
clinical pharmacists on emergent themes. We inter-
viewed providers as well and their comments confirm
the perspectives of the clinical pharmacists. We chose
to include only clinical pharmacists’ quotes in
the wave two results section of the paper because they
were the most descriptive. Though our sample of
clinical pharmacists is relatively small, it represents
the majority of clinical pharmacists at a single VA re-
gion as well as additional clinical pharmacists from a
second geographic region. We would also note that in
this study, we do not capture the perspectives of pa-
tients; this can be an important focus of future work.
The two potential sources of bias that may impact
our results are that we included an interviewee as an
author and that we employed a snowball sampling ap-
proach to identify clinical pharmacists. We invited a
pharmasist investigator [JM] to participate on the
manuscript after data collection was completed and
after initial thematic analysis was drawn on the re-
sults. We chose to do this after collecting the
data when it became apparent that we needed a clin-
ical pharmacist expert to comment on our results
with full depth of understanding. Further, we appreci-
ate that snowball sampling has some inherent limita-
tions in that it may attract like-minded individuals.
However, it is the best method we had to access the
clinical pharmacists. We did not have a master list of
people in this role, so we requested introductions.
Through this, we were able to recruit a meaningful
number that we may not have gotten via cold calling
or emails.
Conclusions
These findings indicate that both providers and clinical
pharmacists see an importance to expand clinical
pharmacist roles in supporting management of complex
pain patients. The potential benefits include reduced
burdens on physicians and better guideline concordant
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opioid based pain care. Implementation barriers to their
role expansion are not insignificant, but with appropriate
targeted strategies, can be addressed. Roles and scopes
of practice need to be clarified in advance. Primary care
providers who work with clinical pharmacists need to
then be made aware of clinical pharmacist scopes and
capabilities. Interdisciplinary collaboration and commu-
nication between the medicine and pharmacy services
will be essential to successful clinical pharmacist role ex-
pansion and shared team prioritization.
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